206548-14-3

Usage

Uses

Since the provided materials do not specify the applications of METHYL 2-AMINO-5-BROMO-3-METHYLBENZENECARBOXYLATE, I can only infer potential uses based on its classification and properties. However, without specific information, the following are general potential applications:
Used in Chemical Synthesis Industry:
METHYL 2-AMINO-5-BROMO-3-METHYLBENZENECARBOXYLATE is used as a synthetic intermediate for the production of various organic compounds and pharmaceuticals, leveraging its unique molecular structure and reactivity.
Used in Research and Development:
As a research compound, METHYL 2-AMINO-5-BROMO-3-METHYLBENZENECARBOXYLATE is used in scientific studies to explore its chemical properties, potential reactions, and possible applications in new chemical processes or products.

Upstream product

• 22223-49-0 methyl 2-amino-3-methylbenzoate 
• 206548-13-2 2-amino-5-bromo-3-methylbenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 5471-82-9 methyl 3-methyl-2-nitrobenzoate 
• 4389-45-1 3-methylantranilic acid 

Downstream Products

• 206546-94-3 5-bromo-2-(4-methoxy-benzenesulfonylamino)-3-methyl-benzoic acid methyl ester 
• 206549-78-2 3-Methyl-5-bromo-2-(4-fluoro-benzenesulfonylamino)-benzoic acid 
• 1217506-31-4 C₂₀H₁₅BrClF₃N₄O₄ 
• 898747-24-5 methyl 5-bromo-1H-indazole-7-carboxylate 
• 1549643-27-7 C₁₁H₉BrN₂O₃ 
• 1588526-61-7 5-bromo-1H-indazole-7-carboxamide 
• 1032667-87-0 methyl 2-amino-5-cyano-3-methylbenzoate 
• 1360957-64-7 (5-bromo-1H-indazol-7-yl)methanol 

Relevant academic research and scientific papers

Rational design of selective inhibitors of PARP4

PARPs (PARP1-16 in humans) are a large family of ADP-ribosyltransferases (ARTs) that have diverse roles in cellular physiology and pathophysiology. Most PARP family members mediate mono-ADP-ribosylation (MARylation) of targets. The function of PARP-mediated MARylation in cells is poorly characterized, due in large part to the paucity of selective small molecule inhibitors of the catalytic activity of individual PARP enzymes. Herein we describe the rational design of selective small molecule inhibitors of PARP4 (also known as vPARP). These inhibitors are based on a quinazolin-4(3H)-one scaffold, and contain substituents at the C-8 position designed to exploit a unique threonine (Thr484, human PARP4 numbering) in the PARP4 nicotinamide sub-pocket. Our most potent analog, AEP07, which contains an iodine at the C-8 position, is at least 12-fold selective over other PARP family members. AEP07 will serve as a useful lead compound for the further development of PARP4 inhibitors that can be used to probe the cellular functions of PARP4 catalytic activity. This journal is

Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators

Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator. Neurotensin receptors have been implicated in a wide variety of CNS disorders, but despite extensive efforts to develop small molecule ligands there are few reports of such compounds. Herein we describe the optimization of a quinazoline based lead to give 18 (SBI-553), a potent and brain penetrant NTR1 allosteric modulator.

BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS

Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Indazole derivatives selectively inhibiting the activity of Janus kinase 1

The present invention relates to indazole derivatives having activity selectively inhibiting Janus kinase 1 (Janananananus Kinase 1) and their use as a therapeutic agent for rheumatoid arthritis.

QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

POLYSUBSTITUTED PYRIDYL PYRAZOLECARBOXAMIDE AND PREPARATION METHOD AND USE THEREOF

The present invention discloses a polysubstituted pyridyl pyrazolecarboxamide and its preparation method and use. The structure of the polysubstituted pyridyl pyrazolecarboxamide of the present invention is shown in the following General Formula I. The po

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

METHOD FOR THE PRODUCTION OF 2-AMINO-5-CYANO-N,3-DIMETHYLBENZAMIDE

The present invention relates to a process for preparing 2-amino-5-cyano-N,3-dimethylbenzamide of formula (1) by reacting 2-amino-5-cyano-3-methylbenzoic esters or diesters with methylamine.

Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group

Selective inhibition of JAK1 has recently been proposed as an appropriate therapeutic rationale for the treatment of inflammatory diseases such as rheumatoid arthritis (RA) In this study, through pairwise comparison and 3D alignment of the JAK isozyme structures bound to the same inhibitor molecule, we reasoned that an alkynol functionality would serve as an isozyme-specific probe group, which would enable the resulting inhibitor to differentiate the ATP-binding site of JAK1 from those of other isozymes The 3-alkynolyl-5- (4′-indazolyl)indazole-7-carboxamide derivatives were thus prepared, and in vitro evaluation of their inhibitory activity against the JAK isozymes revealed that the propargyl alcohol functionality endowed the 5-(4′-indazolyl)indazole-7-carboxamide scaffold with JAK1 selectivity over other JAK isozymes, particularly JAK2